Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Trials. 2017 Jul 11;14(5):518–525. doi: 10.1177/1740774517717722

Table 1.

Cancer Clinical Trials Attitudes and Beliefs (n=127)

Full Sample (n = 127) Race (n = 125) Ethnicity
White (n = 55) African-American (n = 15) Asian (n = 34) Mixed Race (n = 7) Other Race (n = 14) Latino (n = 19) Non-Latino (n = 106)
I believe patients should be told about the option of receiving treatment through a cancer treatment trial. 1.69 (.66) 1.71 (.74) 1.60 (.74) 1.68 (.59) 1.71 (.49) 1.50 (.52) 1.63 (.76) 1.70 (.66)
I believe that cancer treatment trials are important to finding better ways to care for cancer patients. 1.63 (.66) 1.55 (.60) 1.53 (.64) 1.76 (.70) 1.43 (.54) 1.86 (.86) 1.58 (.69) 1.63 (.67)
Healthcare providers like me have an important role in informing cancer patients that a cancer treatment trial may be a quality treatment option. 2.24 (.93) 2.29 (.98) 2.07 (1.0) 2.15 (.82) 2.71 (.76) 2.21 (1.05) 2.16 (.90) 2.25 (.94)
Before referring a patient (to an oncologist, surgeon or other medical practice), I consider if the practice participated in cancer treatment trials. 3.31 (.94) 3.42 (.85) 3.33 (.90) 3.09 (1.08) 3.86 (.69) 3.14 (.95) 3.42 (1.07) 3.29 (.93)
I am willing to initiate a conversation about cancer treatment trials with a patient I am referring for diagnostic testing. 3.08 (1.1) 3.05 (1.1) 2.87 (1.30) 3.06 (1.10) 3.71 (1.3) 3.00 (1.24) 3.05 (1.3) 3.08 (1.12)
I am willing to initiate a conversation about cancer treatment trials with a patient who has been diagnosed with cancer. 2.75 (1.04) 2.64 (1.1) 2.80 (1.1) 2.79 (.91) 2.71 (1.1) 2.93 (1.14) 2.63 (1.17) 2.76 (1.02)
Mean Attitude/Belief Score 2.45 (.62) 2.42 (.65) 2.37 (.65) 2.42 (.63) 2.69 (.42) 2.44 (.65) 2.41 (.65) 2.45 (.62)

Note: All Likert items scored on a scale of 1 (Strongly Agree) to 5 (Strongly Disagree)